Immunobiology and host response to KSHV infection

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 915-928

  Lagos, Dimitrios ^a   Boshoff, Chris ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58849125340     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.053     Document Type: Chapter

References (94)

1. Ablashi, D., Chatlynne, L., Cooper, H. et al. (1999). Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br. J. Cancer, 81, 893-897.
2. Akula, S. M., Pramod, N. P., Wang, F. Z., and Chandran, B. (2002). Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell, 108, 407-419.
3. Ambroziak, J. A., Blackbourn, D. J., Herndier, B. G. et al. (1995). Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science, 268, 582-583.
4. Amyes, E., Hatton, C., Montamat-Sicotte, D. et al. (2003). Char-acterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med., 198, 903-911.
5. Andreoni, M., Sarmati, L., Nicastri, E. et al. (2002). Primary human herpesvirus 8 infection in immunocompetent children. J. Am. Med. Assoc., 287, 1295-1300.
6. Appay, V., Dunbar, P. R., Callan, M. et al. (2002). Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med., 8, 379-385.
7. Banchereau, J. and Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature, 392, 245-252.
8. Bani-Sadr, F., Fournier, S., and Molina, J. M. (2003). Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS, 17, 1580-1581.
9. Bechtel, J. T., Liang, Y., Hvidding J., and Ganem, D. (2003). Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells. J. Virol., 77, 6474-6481.
10. Birkmann, A., Mahr, K., Ensser, A. et al. (2001). Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J. Virol., 75, 11583-11593.
11. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., and Salazar-Mather t5 T. P. (1999). Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu. Rev. Immunol., 17, 189-220.
12. Boshoff, C. and Weiss, R. (2002). AIDS-related malignancies. Nat Rev. Cancer, 2, 373-382.
13. Bourboulia, D., Aldam, D. M., Lagos, D. et al. (2004). Short-and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS, 18, 485-493.
14. Brander, C., O'Connor, P., Suscovich, T. et al. (2001). definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J. Infect. Dis., 184, 119-126.
15. Browning, P. J., Sechler, J. M., Kaplan, M. et al. (1994). Identifica-tion and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood, 84, 2711-2720.
16. Burton, D. R. (2002). Antibodies, viruses and vaccines. Nat. Rev. Immunol., 2, 706-713.
17. Cannon, M. J., Dollard, S. C., Black, J. B. et al. (2003). Risk fac-tors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS, 17, 215-222.
18. Caux, C., Massacrier, C., Vanbervliet, B. et al. (1997). CD34+hematopoietic progenitors from human cord blood differ-entiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating fac-tor plus tumor necrosis factor alpha: II. Functional analysis. Blood, 90, 1458-1470.
19. Cesarman, E., Moore, P. S., Rao, P. H., Inghirami, G., Knowles, D. M., and Chang, Y. (1995). In vitro establishment and characteri-zation of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood, 86, 2708-2714.
20. Chandran, B., Bloomer, C., Chan, S. R., Zhu, L., Goldstein, E., and Horvat, R. (1998). Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts. Virology, 249, 140-149.
21. Crowe, S. M., Carlin, J. B., Stewart, K. I., Lucas, C. R., and Hoy, J. F. (1991). Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J. Acquir. Immune Defic. Syndr., 4, 770-776.
22. Dedicoat, M. and Newton R. (2002). Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br. J. Cancer, 88, 1-3.
23. Della Bella, S., Nicola, S., Brambilla, L. et al. (2006). Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clin. Immunol., 119, 317-329.
24. Dialyna, I.A., Graham, D., Rezaee, R. et al. (2004). Anti-HHV-8/KSHV antibodies in infected individuals inhibit infection in vitro. AIDS, 18, 1263-1270.
25. Dittmer, D., Stoddart, C., Renne, R. et al. (1999). Experimen-tal transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J. Exp. Med., 190, 1857-1868.
26. Donaghy, H., Pozniak, A., Gazzard, B. et al. (2001). Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood, 98, 2574-2576.
27. Donaghy, H., Gazzard, B., Gotch, F., and Patterson, S. (2003). Dys-function and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood, 101, 4505-4511.
28. Dukers, N. H. and Rezza, G. (2003). Human herpesvirus 8 epidemio-logy: What we do and do not know. Aids, 17, 1717-1730.
29. Dupin, N., Fisher, C., Kellam, P. et al. (1999). Distribution of human herpesvirus-8 latently infected cells in Kaposi's sar-coma, multicentric Castleman's disease, and primary effu-sion lymphoma. Proc. Natl Acad. Sci. USA, 96, 4546-4551.
30. Enbom, M., Sheldon, J., Lennette, E. et al. (2000). Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: Variable frequencies found in a multicenter serological study. J. Med. Virol., 62, 498-504.
31. Engels, E. A., Biggar, R. J., Marshall, V. A. et al. (2003). Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS, 17, 1847-1851.
32. Ensoli, B., Barillari, G., Salahuddin, S. Z., Gallo, R. C., and Wong, S. F. (1990). Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature, 345, 84-86.
33. Euvrard, S., Kanitakis, J. and Claudy, A. (2003). Skin cancers after organ transplantation. N. Engl. J. Med., 348, 1681-1691.
34. Gallo, R. C. (1998). The enigmas of Kaposi's sarcoma. Science, 282, 1837-1839.
35. Gao, S. J., Kingsley, L., Hoover, D. R. et al. (1996). Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N. Engl. J. Med., 335, 233-241.
36. Gill, J., Bourboulia, D., Wilkinson, J. et al. (2002). Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and with-out Kaposi sarcoma. J. Acquir. Immune Defic. Syndr., 31, 384-390.
37. Goudsmit, J., Renwick, N., Dukers, N. H. et al. (2000). Human her-pesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): Analysis of seroconversions to ORF65 and ORF73. Proc. Natl Acad. Sci. USA, 97, 4838-4843.
38. Jacobson, L. P., Yamashita, T. E., Detels, R. et al. (1999). Impact of potent anti-retroviral therapy on the incidence of Kaposi's sar-coma and non-Hodgkin's lymphomas among HIV-1 infected individuals. Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr., 21, s34-s41.
39. Kapadia, S. B., Levine, B., Speck S. H., and t. Virgin, H. W. (2002). Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection. Immunity, 17, 143-155.
40. Kedes, D. H., Operskalski, E., Busch, M., Kohn, R., Flood J., and Ganem, D. (1996). The seroepidemiology of human her-pesvirus 8 (Kaposi's sarcoma-associated herpesvirus): Distri-bution of infection in KS risk groups and evidence for sexual transmission. Nat. Med., 2, 918-924.
41. Kim, I. J., Flano, E., Woodland D. L., and Blackman M. A. (2002). Antibody-mediated control of persistent gamma-herpesvirus infection. J. Immunol., 168, 3958-3964.
42. Kimball, L. E., Casper, C., Koelle, D. M. et al. (2004). Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated her-pesvirus in persons with a history of Kaposi sarcoma. J. Infect. Dis., 189, 2016-2022.
43. Lallemand, F., Desire, N., Rozenbaum, W., Nicolas J. C., and Marechal V. (2000). Quantitative analysis of human her-pesvirus 8 viral load using a real-time PCR assay. J. Clin. Micro-biol., 38, 1404-1408.
44. Lam, L. L., Pau, C. P., Dollard, S. C., Pellett, P. E., and Spira, T. J. (2002). Highly sensitive assay for human herpesvirus 8 antibodies that uses a multiple antigenic peptide derived from open reading frame K8.1. J. Clin. Microbiol., 40, 325-329.
45. Larcher, C., Nguyen, V. A., Furhapter, C. et al. (2005). Human herpesvirus-8 infection of umbilical cord-blood-derived CD34+ stem cells enhances the immunostimulatory function of their dendritic cell progeny. Exp. Dermatol., 14, 41-49.
46. Lehrnbecher, T. L., Foster, C. B., Zhu, S. et al. (2000). Variant geno-types of FcgammaRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood, 95, 2386-2390.
47. Lin, S. F., Sun, R., Heston, L. et al. (1997). Identification, expres-sion, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen. J. Virol., 71, 3069-3076.
48. Macsween, K. F. and Crawford, D. H. (2003). Epstein-Barr virus-recent advances. Lancet Infect. Dis., 3, 131-140.
49. Martin, J. N. (2003). Diagnosis and epidemiology of human her-pesvirus 8 infection. Semin. Hematol., 40, 133-142.
50. Mbulaiteye, S. M., Biggar, R. J., Goedert, J. J., and Engels, E. A. (2003). Immune Deficiency and risk for malignancy among persons with AIDS. J. Acquir. Immune Defic. Syndr., 32, 527-533.
51. Medzhitov, R. and Janeway, C. A. Jr. (2002). Decoding the patterns of self and nonself by the innate immune system. Science, 296, 298-300.
52. Micheletti, F., Monini, P. Fortini, C. et al. (2002). Identification of cytotoxic T-lymphocyte epitopes of human herpesvirus 8. Immunology, 106, 395-403.
53. Moore, P. S. and Chang Y. (2003). Kaposi's Sarcoma-associated her-pesvirus immunoevasion and tumorigenesis: Two sides of the same coin? Annu. Rev. Microbiol., 57, 609-639.
54. Moretta, A., Bottino, C., Mingari, M. C., Biassoni, and Moretta, L. (2002). What is a natural killer cell? Nat. Immunol., 3, 6-8.
55. Murgia, C., Pritchard, J. K., Kim, S. Y. et al. (2006). Clonal origin and evolution of a transmissible cancer. Cell, 126, 477-487.
56. Oksenhendler, E., Cazals-Hatem, D., Schultz, T. F. et al. (1998). Tran-sient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection. N. Engl. J. Med., 338, 1585-1591.
57. Orange, J. S., Fassett, M. S., Koopman, L. A., Boyson, J. E., and Stro-minger, J. L. (2002). Viral evasion of natural killer cells. Nature Immunol., 3, 1006-1012.
58. Osman, M., Kubo, T., Gill, J. et al. (1999). Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J. Virol., 73, 6136-6140.
59. Patterson, S. (2000). Flexibility and cooperation among dendritic cells. Nat. Immunol., 1, 273-274.
60. Pauk, J., Huang, M.-L., Brodie, S. J. et al. (2000). Mucosal shedding of human herpesvirus 8 in men. N. Engl. J. Med., 343, 1369-1377.
61. Pellett, P. E., Wright, D. J. Engels, E. A. et al. (2003). Multicenter comparison of serologic assays and estimation of human her-pesvirus 8 seroprevalence among US blood donors. Transfusion, 43, 1260-1268.
62. Ploegh, H. L. (1998). Viral strategies of immune evasion. Science, 280, 248-253.
63. Rabkin, C. S., Schulz, T. F., Whitby, D. et al. (1998). Interassay cor-relation of human herpesvirus 8 serologic tests. J. Infect. Dis., 178, 304-309.
64. Rappocciolo, G., Jenkins, F.J., Hensler, H.R. et al. (2006). DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J. Immunol., 176, 1741-1749.
65. Renne, R., Lagunoff, M., Zhong, W., and Ganem, D. (1996). The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J. Virol., 70, 8151-8154.
66. Ribechini, E., Fortini, C., Marastoni, M. et al. (2006). Identification of CD8+ T cell epitopes within lytic antigens of human herpes virus 8. J. Immunol., 176, 923-930.
67. Sallusto, F. and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is main-tained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 179, 1109-1118.
68. Sarid, R., Olsen, S. J., and Moore, P. S. (1999). Kaposi's sarcoma-associated herpesvirus: Epidemiology, virology, and molecular biology. Adv. Virus Res., 52, 139-232.
69. Schatz, O., Monini, P., Bugarini, R. et al. (2001). Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: Mul-ticentre study with multiple and novel assays. J. Med. Virol., 65 123-132.
70. Sgadari, C., Barillari, G., Toschi, E. et al. (2002). HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Med., 8, 225-232.
71. Shortman, K. and Liu, Y. J. (2002). Mouse and human dendritic cell subtypes. Nat. Rev. Immunol., 2, 151-161.
72. Simpson, G. R., Schulz, T. F., Whitby, D. et al. (1996). Preva-lence of Kaposi's sarcoma associated herpesvirus infec-tion measured by antibodies to recombinant capsid protein and latent immunofiuorescence antigen. Lancet, 348, 1133-1138.
73. Sirianni, M. C., Uccini, S., Angeloni, A. Faggioni, A., Cottoni, F., and Ensoli B. (1997). Circulating spindle cells: Correlation with human herpesvirus-8 (HHV-8) infection and Kaposi's sar-coma. Lancet, 349, 255.
74. Sirianni, M. C., Vincenzi, L., Topino, S. et al. (2002). NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur. J. Immunol., 32, 2711-2720.
75. Sitas, F. and Newton R. (2001). Kaposi's sarcoma in South Africa. J. Natl Cancer Inst. Monogr., 1-4.
76. Sitas, F., Carrara, H., Beral, V. et al. (1999). Antibodies against human herpesvirus 8 in black south African patients with cancer. N. Engl. J. Med., 340, 1863-1871.
77. Spiller, O. B., Robinson, M., O'Donnell, E. et al. (2003). Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J. Virol., 77, 592-599.
78. Spira, T. J., Lam, L., Dollard, S. C. et al. (2000). Comparison of sero-logic assays and PCR for diagnosis of human herpesvirus 8 infection. J. Clin. Microbiol., 38, 2174-2180.
79. Stebbing, J., Bourboulia, D., Johnson, M. et al. (2003a). KSHV spe-cific CTLs recognize and target Darwinian positively selected autologous K1 epitopes. J. Virol., 77, 4306-4314.
80. Stebbing, J., Gazzard, B., Portsmouth, S. et al. (2003b). Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood, 102, 1806-1814.
81. Strickler, H. D., Goedert, J. J. Bethke, F. R. et al. (1999). Human Her-pesvirus 8 cellular immune responses in homosexual men. J. Infect. Dis., 180, 1682-1685.
82. Valcuende-Cavero, F., Febrer-Bosch M. I., and Castells-Rodellas, A. (1994). Langerhans cells and lymphocytic infiltrate in AIDS-associated Kaposi's sarcoma. An immunohistochemical study. Acta. Derm. Venereol., 74, 183-187.
83. Walport, M. J. (2001a). Complement. First of two parts. N. Engl. J. Med., 344, 1058-1066.
84. Walport, M. J. (2001b). Complement. Second of two parts. N. Engl. J. Med., 344, 1140-1144.
85. Wang, Q. J., Jenkins, F. J., Jacobson, L. P. et al. (2000). CD8+ cyto-toxic T lymphocyte responses to lytic proteins of human her-pes virus 8 in human immunodeficiency virus type 1-infected and-uninfected Individuals. J. Infect. Dis., 182, 928-932.
86. Wang, Q. J., Jenkins, F. J., Jacobson, L. P. et al. (2001). Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood, 97, 2366-2373.
87. Wang, Q. J., Huang, X. L., Rappocciolo, G. et al. (2002). Identification of an HLA A? 0201-restricted CD8 (+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood, 99, 3360-3366.
88. Wang, H. S., Trotter M. W., Lagos, D. et al. (2004). Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Gen., 36, 687-693
89. Wilkinson, J., Cope, A., Gill, J. et al. (2002). Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J. Virol., 76, 2634-2640.
90. Woodberry, T., Suscovich, T. J., Henry, L. M. et al. (2005). Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. J. Infect. Dis., 192, 622-629.
91. Wu, W., Vieira, J., Fiore, N. et al. (2006). KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: Persistence of infection during hematopoiesis in vitro and in vivo. Blood, 108, 141-151.
92. Yewdell, J. W. and Hill, A. B. (2002). Viral interference with antigen presentation. Nat. Immunol., 3, 1019-1025.
93. Ziegler, J., Newton, R., Bourboulia, D. et al. (2003). Risk factors for Kaposi's sarcoma: A case-control study of HIV-seronegative people in Uganda. Int. J. Cancer, 103, 233-240.
94. Zong, J. C., Ciufo, D. M. Alcendor, D. J. et al. (1999). High-level vari-ability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. J. Virol., 73, 4156-4170.